In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Grupo J Uriach S.L.

http://www.uriach.com/en/

Latest From Grupo J Uriach S.L.

Finance Watch: SPAC Deals Stumble, Layoffs Continue As Valuations Struggle To Recover

Aesther Healthcare Acquisition extended the deadline to merge with Ocean Biomedical, while Intrinsic Medicine no longer plans to go public by merging with a SPAC. In restructuring news, Otonomy begins liquidation, Celyad cuts last clinical program with cash running out and Clovis files for bankruptcy.

Financing Restructuring

Will Genus Claims Be Resuscitated? Supreme Court To Decide In Amgen PCSK9 Patent Dispute

High court will consider the standard for determining if a patent covering a group of related chemicals is enabled in Amgen v. Sanofi. It denies Juno petition seeking review of standard for written description of an invention in CAR T-cell patent suit against Kite.

Intellectual Property Legal Issues

Academic Study Boosts Belief In TIL Therapies, Including Iovance’s Lifileucel

A new academic study presented at ESMO has provided the first Phase III data for tumor-infiltrating lymphocytes as a potential new therapeutic class, while industry leader Iovance looks set to have early-stage data for its TIL accepted by the US FDA.

Cancer Clinical Trials

Finance Watch: 3T Biosciences Emerges With $40m And Novel TCR Platform

Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.

Financing Innovation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Palau Pharma S.A.
    • TheraLab
    • LABOREST Italia S.p.A.
    • J. Uriach y Compañía, S.A.
    • Uriach OTC, S.L.
    • Corporacion J. Uriach, S.A.
    • Casa Pronat S.L.
UsernamePublicRestriction

Register